[Treatment of metastatic @entity2971 with @entity2879 and XXXX as first line chemotherapy].

@entity1 @entity137 @entity41 @entity2971 @entity5 @entity39 @entity900 @entity2879 @entity4797 @entity32799 @entity44
PURPOSE: The efficacy and @entity137 of two-drug therapy ( @entity2879 and @entity900 , EP) in @entity1 with metastatic @entity2971 were investigated. @entity1 AND METHODS: Between December 1996 and November 1999, 18 @entity1 with metastatic @entity2971 (6 @entity4797 and 12 @entity4797 , Stage II 8, Stage IIIA 2, Stage IIIB 6, Stage IIIC 2) were treated by 3-5 cycles of induction chemotherapy regimen (EP). @entity2879 and @entity900 were administrated in doses of 100 mg/m2 and 20 mg/m2, respectively, on days 1 to 5 and then repeated from day 21. After @entity5 markers obtained normal levels, one or two additional cycles of EP were continued. @entity1 showing evidence of @entity41 mass underwent debulking surgery as early as possible. RESULTS: At the end of EP therapy, 4 (22%) of the 18 @entity1 achieved complete remission and 14 @entity1 (78%) showed partial remission. Seven @entity1 of partial remission were treated by excision of residual abnormalities: 6 had pathologically @entity39 in the resected specimen and 1 had @entity44 , and these 7 @entity1 all achieved complete remission. Four other @entity1 achieving partial remission were followed without surgical excision and have had no evidence of disease progression. Remaining three @entity1 achieving partial remission received salvage chemotherapy with or without adjunctive surgery, resulted in complete remission in 2 @entity1 and partial remission in 1 @entity1 . EP demonstrated to have less treatment-related @entity137 compared with that of @entity32799 . Follow up studies ranging from 12 to 47 months (median, 29.6) showed that one @entity1 experienced a relapse from complete remission at 13 months and was salvaged by chemotherapy and surgery. Finally, thirteen @entity1 (72%) who achieved complete remission are alive and disease-free and 5 @entity1 (28%) showing partial remission are alive with negative @entity5 markers and no evidence of relapse. CONCLUSION: These results suggests that EP is an efficacious and less toxic first line regimen for good-prognosis @entity1 with metastatic @entity2971 .
